ATE411295T1 - 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung - Google Patents

2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung

Info

Publication number
ATE411295T1
ATE411295T1 AT05770962T AT05770962T ATE411295T1 AT E411295 T1 ATE411295 T1 AT E411295T1 AT 05770962 T AT05770962 T AT 05770962T AT 05770962 T AT05770962 T AT 05770962T AT E411295 T1 ATE411295 T1 AT E411295T1
Authority
AT
Austria
Prior art keywords
benzoäüindazole
carbamat
derivatives
preparation
therapeutic use
Prior art date
Application number
AT05770962T
Other languages
German (de)
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Christian Maloizel
Mireille Sevrin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE411295T1 publication Critical patent/ATE411295T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AT05770962T 2004-05-11 2005-05-10 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung ATE411295T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405055A FR2870239B1 (fr) 2004-05-11 2004-05-11 Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
ATE411295T1 true ATE411295T1 (de) 2008-10-15

Family

ID=34947852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770962T ATE411295T1 (de) 2004-05-11 2005-05-10 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung

Country Status (32)

Country Link
US (3) US7501449B2 (enExample)
EP (1) EP1747201B8 (enExample)
JP (1) JP4909889B2 (enExample)
KR (1) KR101165483B1 (enExample)
CN (1) CN100577648C (enExample)
AR (1) AR049090A1 (enExample)
AT (1) ATE411295T1 (enExample)
AU (1) AU2005251982B2 (enExample)
BR (1) BRPI0508563A (enExample)
CA (1) CA2557942C (enExample)
CR (1) CR8570A (enExample)
CY (1) CY1108710T1 (enExample)
DE (1) DE602005010418D1 (enExample)
DK (1) DK1747201T3 (enExample)
EC (1) ECSP066810A (enExample)
ES (1) ES2315898T3 (enExample)
FR (1) FR2870239B1 (enExample)
HR (1) HRP20090012T3 (enExample)
IL (1) IL177632A (enExample)
MA (1) MA28372A1 (enExample)
NO (1) NO20064073L (enExample)
NZ (1) NZ549330A (enExample)
PL (1) PL1747201T3 (enExample)
PT (1) PT1747201E (enExample)
RS (1) RS50724B (enExample)
RU (1) RU2379293C2 (enExample)
SI (1) SI1747201T1 (enExample)
TN (1) TNSN06258A1 (enExample)
TW (1) TWI349004B (enExample)
UA (1) UA85866C2 (enExample)
WO (1) WO2005121099A1 (enExample)
ZA (1) ZA200607244B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
WO2007088528A1 (en) * 2006-02-03 2007-08-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Microtubule targeting agents
CL2008000793A1 (es) * 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
MX2016000669A (es) * 2013-07-15 2016-11-11 Basf Se Compuestos plaguicidas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
FR2741073B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives de 4,5-dihydroimidazo(1,2-a)pyrrolo(1,2,3-cd) benzimidazole, leur preparation et leur application en therapeutique
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
MXPA03001945A (es) * 2000-09-06 2003-09-10 Neurogen Corp Tetrahidroindazoles sustituidos con arilo y su uso como ligandos para el receptor gaba-a.
ATE425148T1 (de) * 2000-09-18 2009-03-15 Eisai R&D Man Co Ltd Triazinone sowie deren medizinale anwendung
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
EP1747201A1 (fr) 2007-01-31
AR049090A1 (es) 2006-06-28
UA85866C2 (uk) 2009-03-10
DK1747201T3 (da) 2009-02-16
AU2005251982B2 (en) 2011-04-28
EP1747201B1 (fr) 2008-10-15
TWI349004B (en) 2011-09-21
ES2315898T3 (es) 2009-04-01
JP2007537212A (ja) 2007-12-20
AU2005251982A1 (en) 2005-12-22
IL177632A (en) 2012-07-31
WO2005121099A1 (fr) 2005-12-22
PT1747201E (pt) 2009-01-19
US8114899B2 (en) 2012-02-14
US7501449B2 (en) 2009-03-10
US20090143380A1 (en) 2009-06-04
CY1108710T1 (el) 2014-04-09
US20070105932A1 (en) 2007-05-10
US20120108584A1 (en) 2012-05-03
HRP20090012T3 (en) 2009-02-28
MA28372A1 (fr) 2006-12-01
IL177632A0 (en) 2006-12-31
PL1747201T3 (pl) 2009-04-30
KR20070007796A (ko) 2007-01-16
FR2870239A1 (fr) 2005-11-18
DE602005010418D1 (de) 2008-11-27
FR2870239B1 (fr) 2006-06-16
RU2379293C2 (ru) 2010-01-20
NO20064073L (no) 2006-11-06
CN100577648C (zh) 2010-01-06
ZA200607244B (en) 2008-04-30
CA2557942A1 (fr) 2005-12-22
NZ549330A (en) 2010-08-27
RS50724B (sr) 2010-08-31
US8258168B2 (en) 2012-09-04
CA2557942C (fr) 2013-08-06
CN1930131A (zh) 2007-03-14
TW200604181A (en) 2006-02-01
JP4909889B2 (ja) 2012-04-04
BRPI0508563A (pt) 2007-08-14
RU2006132325A (ru) 2008-03-20
TNSN06258A1 (fr) 2007-12-03
ECSP066810A (es) 2006-11-16
EP1747201B8 (fr) 2009-02-18
CR8570A (es) 2007-10-04
HK1104288A1 (en) 2008-01-11
KR101165483B1 (ko) 2012-07-13
SI1747201T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE502005002105D1 (de) 4-benzimidazol-2-yl-pyridazin-3-on-derivative, ihre herstellung und verwendung in arzneimitteln
DE602005021501D1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE432701T1 (de) Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
DE602004021384D1 (de) Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
ATE540023T1 (de) Neuartige 3-aminoalkyl-1,3-dihydro-2h-indol-2-on- derivate, ihre herstellung und therapeutische verwendung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
TWI350287B (en) Acylaminothiazole derivatives, their preparation and their therapeutic application
ATE499351T1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung
EP1968616A4 (en) DERIVATIVES OF SULINDAC, USE AND PREPARATION THEREOF
DE602006005246D1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
ATE474840T1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
DE602006010337D1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie
ATE411295T1 (de) 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung
DE602004021383D1 (de) Indol-7 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
DE602006008971D1 (de) N-ä(4,5-diphenylpyrimidin-2-yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung
IL180484A0 (en) 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof
DE602005004876D1 (de) Methylendioxyoctahydroindenderivate, deren Herstellung und deren Verwendung als Duftstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1747201

Country of ref document: EP